Jann-Frederik Cremers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jann-Frederik Cremers has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Sabine Kliesch
Centre of Reproductive Medicine and Andrology, Department of Clinical and Surgical Andrology, University Hospital Münster, Münster, Germany
7 shared publications - Michael Zitzmann
Faculty of Medicine, University of Muenster Germany, Domagkstrasse 3, 48149 Muenster, Germany
5 shared publications - Sandra Laurentino
Centre of Reproductive Medicine and Andrology, Institute of Reproductive and Regenerative Biology, University of Münster, Münster, Germany
3 shared publications - Armin Soave
Department of Urology University Medical Center Hamburg‐Eppendorf Hamburg Germany
2 shared publications - Claudia Krallmann
Department of Andrology, Centre of Reproductive Medicine and Andrology (CeRA), University Hospital Münster
2 shared publications Frank Tuettelmann
Institute of Reproductive Genetics, Centre of Medical Genetics, University of Münster, Münster, Germany
2 shared publications
Latest Publications
- 4 November 2026
- Published by Springer Nature in Die Urologie
- p. 1-7
Andrologische Aspekte bei urologischen Traumata
- 4 November 2026
- Published by Springer Nature in Die Urologie
- p. 1-7
Andrologische Aspekte bei urologischen Traumata
- Open Access
A single-nucleus multiomic and spatial atlas of gene regulation in human spermatogenesis
Gametogenesis, the production of oocytes and sperm, ensures the faithful transmission of genetic material to the next generation. In males, spermatogenesis occurs within the testis, where germ cells progress through a highly ordered developmental programme in close association with supporting somatic cells. Defects in this process cause infertility, yet the gene regulatory mechanisms coordinating normal and dysfunctional human spermatogenesis remain incompletely defined. Here we generate a single-nucleus multiomic and spatial atlas of human spermatogenesis by profiling chromatin accessibility and gene expression in the same nuclei and integrating these data with spatial transcriptomics of intact testicular tissue. We infer high-confidence gene regulatory networks that resolve stage-specific activity of known and novel candidate regulators across germline and somatic compartments, and map spatially restricted signalling interactions within the seminiferous tubule niche. Integration with infertility-associated genetic variation links non-coding risk loci to candidate enhancers and target genes in cell-type-specific regulatory contexts. Finally, profiling clinical cryptozoospermia samples as in vivo perturbations supports the ability of this network to capture downstream transcriptional consequences of disease-associated regulatory disruption. Together, these data provide a spatially resolved regulatory framework for human spermatogenesis and a foundation for interpreting the molecular basis of male infertility.
Open AccessA single-nucleus multiomic and spatial atlas of gene regulation in human spermatogenesis
Gametogenesis, the production of oocytes and sperm, ensures the faithful transmission of genetic material to the next generation. In males, spermatogenesis occurs within the testis, where germ cells progress through a highly ordered developmental programme in close association with supporting somatic cells. Defects in this process cause infertility, yet the gene regulatory mechanisms coordinating normal and dysfunctional human spermatogenesis remain incompletely defined. Here we generate a single-nucleus multiomic and spatial atlas of human spermatogenesis by profiling chromatin accessibility and gene expression in the same nuclei and integrating these data with spatial transcriptomics of intact testicular tissue. We infer high-confidence gene regulatory networks that resolve stage-specific activity of known and novel candidate regulators across germline and somatic compartments, and map spatially restricted signalling interactions within the seminiferous tubule niche. Integration with infertility-associated genetic variation links non-coding risk loci to candidate enhancers and target genes in cell-type-specific regulatory contexts. Finally, profiling clinical cryptozoospermia samples as in vivo perturbations supports the ability of this network to capture downstream transcriptional consequences of disease-associated regulatory disruption. Together, these data provide a spatially resolved regulatory framework for human spermatogenesis and a foundation for interpreting the molecular basis of male infertility.
- Open Access
Can Hormonal Therapy Improve the Outcomes of mTESE in Patients With Non‐Obstructive Azoospermia?
Background: Non‐obstructive azoospermia (NOA) represents the most severe form of male infertility. Hypogonadism is common in NOA patients, and normal testosterone (T) levels are considered essential for spermatogenesis. Fertility‐preserving hormonal therapy (FpHT) has been proposed to optimize hormonal milieu and improve sperm retrieval rates (SRR) at microdissection testicular sperm extraction (mTESE), although evidence remains controversial and meta‐analyses have not shown consistent benefit. Aims: To determine whether FpHT improves SRR in hypogonadal men with NOA undergoing mTESE. Methods: We retrospectively evaluated 1256 selected men with NOA (601 Klinefelter syndrome [KS], 655 normal karyotype) from a cohort of 3086 men who underwent mTESE at our tertiary andrology center between 2010 and 2024. Patients with obstructive azoospermia, prior gonadotoxic exposure, or hypogonadotropic hypogonadism were excluded. All participants underwent comprehensive clinical, hormonal, and genetic assessment. Comparisons were performed between eugonadal and hypogonadal patients, and within the hypogonadal group, between those who received FpHT and those who did not. Results: Hypogonadism was present in 49.9% of patients, predominantly in KS ( p < 0.001). FpHT significantly increased serum T levels in both groups (ΔT +3.1 nmol/L in KS; +5.6 nmol/L in 46, XY; p < 0.001). However, despite biochemical normalization, FpHT did not improve SRR in either karyotypic group (overall SRR: 32.4%). Multivariate analysis identified younger age as the sole independent predictor of successful retrieval in KS ( p = 0.011). Conclusion: FpHT restores serum androgen levels but does not improve spermatogenic activity or sperm retrieval rates in men with NOA. These findings support current EAU guidelines and indicate that FpHT should be used to treat symptomatic hypogonadism rather than to enhance fertility outcomes before mTESE.
Open AccessCan Hormonal Therapy Improve the Outcomes of mTESE in Patients With Non‐Obstructive Azoospermia?
Background: Non‐obstructive azoospermia (NOA) represents the most severe form of male infertility. Hypogonadism is common in NOA patients, and normal testosterone (T) levels are considered essential for spermatogenesis. Fertility‐preserving hormonal therapy (FpHT) has been proposed to optimize hormonal milieu and improve sperm retrieval rates (SRR) at microdissection testicular sperm extraction (mTESE), although evidence remains controversial and meta‐analyses have not shown consistent benefit. Aims: To determine whether FpHT improves SRR in hypogonadal men with NOA undergoing mTESE. Methods: We retrospectively evaluated 1256 selected men with NOA (601 Klinefelter syndrome [KS], 655 normal karyotype) from a cohort of 3086 men who underwent mTESE at our tertiary andrology center between 2010 and 2024. Patients with obstructive azoospermia, prior gonadotoxic exposure, or hypogonadotropic hypogonadism were excluded. All participants underwent comprehensive clinical, hormonal, and genetic assessment. Comparisons were performed between eugonadal and hypogonadal patients, and within the hypogonadal group, between those who received FpHT and those who did not. Results: Hypogonadism was present in 49.9% of patients, predominantly in KS ( p < 0.001). FpHT significantly increased serum T levels in both groups (ΔT +3.1 nmol/L in KS; +5.6 nmol/L in 46, XY; p < 0.001). However, despite biochemical normalization, FpHT did not improve SRR in either karyotypic group (overall SRR: 32.4%). Multivariate analysis identified younger age as the sole independent predictor of successful retrieval in KS ( p = 0.011). Conclusion: FpHT restores serum androgen levels but does not improve spermatogenic activity or sperm retrieval rates in men with NOA. These findings support current EAU guidelines and indicate that FpHT should be used to treat symptomatic hypogonadism rather than to enhance fertility outcomes before mTESE.
- Open Access
- 27 November 2025
- Published by Taylor & Francis in The Aging Male
- Vol. 28 (1) , 2591471
Risk-dependent decision-making for circumcision in penile corporoplasty: type 2 diabetes mellitus associated with post-surgical phimosis
Corporoplasty is typically accompanied by circumcision to prevent complications such as phimosis, foreskin edema, and necrosis, yet supporting evidence is limited. We reassessed the need for concomitant circumcision by quantifying postoperative phimosis and exploring associated comorbidities. In this single-centre retrospective cohort study, 69 of 191 men who underwent corporoplasty between 2010 and 2023 met predefined criteria. Patients with incomplete records, refusal to participate, or loss to follow-up were excluded. Data collection involved the administration of a questionnaire to patients, supplemented by data retrieved from medical databases. The median age was 55 years (range 17-70 years). 48 of 69 patients did not undergo circumcision either before or during the corporoplasty. Only 3 out of the 48 patients (6.25%) developed post-surgical phimosis. No post-surgical foreskin necrosis were reported. A relevant finding was type2 diabetes mellitus as a significant risk factor for post-surgical phimosis (p < 0.0038). Additionally, the negative impact of the degree of curvature on post-surgical glans penis sensitivity was identified (p = 0.027). Our findings advocate against the obligatory practice of circumcision performing corporoplasty. Nonetheless, our results emphasize the importance of counseling patients with type2 diabetes mellitus due to their heightened susceptibility to post-surgical phimosis development.
- 27 November 2025
- Published by Taylor & Francis in The Aging Male
- Vol. 28 (1) , 2591471
Open AccessRisk-dependent decision-making for circumcision in penile corporoplasty: type 2 diabetes mellitus associated with post-surgical phimosis
Corporoplasty is typically accompanied by circumcision to prevent complications such as phimosis, foreskin edema, and necrosis, yet supporting evidence is limited. We reassessed the need for concomitant circumcision by quantifying postoperative phimosis and exploring associated comorbidities. In this single-centre retrospective cohort study, 69 of 191 men who underwent corporoplasty between 2010 and 2023 met predefined criteria. Patients with incomplete records, refusal to participate, or loss to follow-up were excluded. Data collection involved the administration of a questionnaire to patients, supplemented by data retrieved from medical databases. The median age was 55 years (range 17-70 years). 48 of 69 patients did not undergo circumcision either before or during the corporoplasty. Only 3 out of the 48 patients (6.25%) developed post-surgical phimosis. No post-surgical foreskin necrosis were reported. A relevant finding was type2 diabetes mellitus as a significant risk factor for post-surgical phimosis (p < 0.0038). Additionally, the negative impact of the degree of curvature on post-surgical glans penis sensitivity was identified (p = 0.027). Our findings advocate against the obligatory practice of circumcision performing corporoplasty. Nonetheless, our results emphasize the importance of counseling patients with type2 diabetes mellitus due to their heightened susceptibility to post-surgical phimosis development.
- Open Access
Cardiovascular safety of testosterone therapy—Insights from the TRAVERSE trial and beyond: A position statement of the European Expert Panel for Testosterone Research
Introduction: Testosterone therapy has become a cornerstone treatment for men with hypogonadism, offering significant benefits such as improved sexual function, mood, muscle mass, and bone density. However, concerns about its cardiovascular safety have historically tempered its use. This position statement synthesizes the current evidence on the cardiovascular safety of testosterone therapy, drawing from key studies including the TRAVERSE trial, other trials, and recent meta‐analyses. Background and importance: Testosterone therapy aims to restore testosterone levels in men with hypogonadism, a condition associated with increased cardiovascular and metabolic risks. Early research produced mixed results, with some studies suggesting a potential increase in cardiovascular events such as myocardial infarction and stroke, while others indicated possible cardiovascular benefits, particularly in men with coexisting conditions like metabolic syndrome and type 2 diabetes. Findings from recent studies: The TRAVERSE trial, a large‐scale, randomized, placebo‐controlled study, provided robust evidence that testosterone therapy does not significantly increase the risk of major adverse cardiovascular events. Testosterone therapy was found to effectively mitigate anemia in hypogonadal men, highlighting a dual benefit of increasing red blood cell production while managing cardiovascular risks. The findings from the TRAVERSE trial align with those from previous meta‐analyses that concluded that testosterone therapy is safe and does not increase cardiovascular risk. Consensus and clinical implications: There is consensus that testosterone therapy, when prescribed to appropriately selected patients and monitored regularly, is safe from a cardiovascular standpoint, with the potential benefits outweighing the risks when the therapy is used responsibly. Current guidelines recommend individualized treatment plans with careful monitoring, especially of hematocrit levels. This position statement amalgamates previous knowledge with current data and is in agreement with recent United States Food and Drug Administration label changes for testosterone products.
Open AccessCardiovascular safety of testosterone therapy—Insights from the TRAVERSE trial and beyond: A position statement of the European Expert Panel for Testosterone Research
Introduction: Testosterone therapy has become a cornerstone treatment for men with hypogonadism, offering significant benefits such as improved sexual function, mood, muscle mass, and bone density. However, concerns about its cardiovascular safety have historically tempered its use. This position statement synthesizes the current evidence on the cardiovascular safety of testosterone therapy, drawing from key studies including the TRAVERSE trial, other trials, and recent meta‐analyses. Background and importance: Testosterone therapy aims to restore testosterone levels in men with hypogonadism, a condition associated with increased cardiovascular and metabolic risks. Early research produced mixed results, with some studies suggesting a potential increase in cardiovascular events such as myocardial infarction and stroke, while others indicated possible cardiovascular benefits, particularly in men with coexisting conditions like metabolic syndrome and type 2 diabetes. Findings from recent studies: The TRAVERSE trial, a large‐scale, randomized, placebo‐controlled study, provided robust evidence that testosterone therapy does not significantly increase the risk of major adverse cardiovascular events. Testosterone therapy was found to effectively mitigate anemia in hypogonadal men, highlighting a dual benefit of increasing red blood cell production while managing cardiovascular risks. The findings from the TRAVERSE trial align with those from previous meta‐analyses that concluded that testosterone therapy is safe and does not increase cardiovascular risk. Consensus and clinical implications: There is consensus that testosterone therapy, when prescribed to appropriately selected patients and monitored regularly, is safe from a cardiovascular standpoint, with the potential benefits outweighing the risks when the therapy is used responsibly. Current guidelines recommend individualized treatment plans with careful monitoring, especially of hematocrit levels. This position statement amalgamates previous knowledge with current data and is in agreement with recent United States Food and Drug Administration label changes for testosterone products.
- Open Access
- 19 December 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-15
Histone variant H3.5 in testicular cell differentiation and its interactions with histone chaperones
Testicular cell differentiation is a highly regulated process, essential for male reproductive health. The histone variant H3.5 is apparently a critical player in this intricate orchestra of cell types, but its regulation and function remains poorly understood. To elucidate its role, we fractionized testicular cells using c-Kit/CD117 as a separation marker and analyzed H3.5 expression. Further, we investigated the regulation of H3.5 expression using public data repositories. We explored DNA methylation patterns in specific regions of the H3-5 gene and assessed H3-5 copy number gain in seminoma specimens. Additionally, we examined the testicular localization of H3.5 and its histone chaperone interactions to understand its regulation at the protein level. We used qRT-PCR, MeDIP, and qPCR to study H3.5 expression and DNA methylation in various cell types. H3-5 copy number gain was analyzed using qPCR. Protein interactions were investigated through fluorescence-2-hybrid assays in baby hamster kidney cells. H3.5 is primarily enriched in spermatocytes. DNA methylation of a CpG island overlapping the H3-5 promoter appeared to be involved in the tissue-specific regulation of H3.5 expression. Elevated H3.5 expression was observed in seminoma specimens, suggesting a potential link to testicular tumors. H3-5 copy number gain was associated with elevated H3.5 expression in seminoma specimens. Furthermore, we identified physical interactions between H3.5 and histone chaperones Asf1a and Asf1b, HIRA, CAF p150 and DAXX, shedding light on the protein-level regulation of H3.5. These findings provide valuable insights into the molecular mechanisms governing testicular cell differentiation and the potential role of H3.5 in testicular pathologies.
- 19 December 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-15
Open AccessHistone variant H3.5 in testicular cell differentiation and its interactions with histone chaperones
Testicular cell differentiation is a highly regulated process, essential for male reproductive health. The histone variant H3.5 is apparently a critical player in this intricate orchestra of cell types, but its regulation and function remains poorly understood. To elucidate its role, we fractionized testicular cells using c-Kit/CD117 as a separation marker and analyzed H3.5 expression. Further, we investigated the regulation of H3.5 expression using public data repositories. We explored DNA methylation patterns in specific regions of the H3-5 gene and assessed H3-5 copy number gain in seminoma specimens. Additionally, we examined the testicular localization of H3.5 and its histone chaperone interactions to understand its regulation at the protein level. We used qRT-PCR, MeDIP, and qPCR to study H3.5 expression and DNA methylation in various cell types. H3-5 copy number gain was analyzed using qPCR. Protein interactions were investigated through fluorescence-2-hybrid assays in baby hamster kidney cells. H3.5 is primarily enriched in spermatocytes. DNA methylation of a CpG island overlapping the H3-5 promoter appeared to be involved in the tissue-specific regulation of H3.5 expression. Elevated H3.5 expression was observed in seminoma specimens, suggesting a potential link to testicular tumors. H3-5 copy number gain was associated with elevated H3.5 expression in seminoma specimens. Furthermore, we identified physical interactions between H3.5 and histone chaperones Asf1a and Asf1b, HIRA, CAF p150 and DAXX, shedding light on the protein-level regulation of H3.5. These findings provide valuable insights into the molecular mechanisms governing testicular cell differentiation and the potential role of H3.5 in testicular pathologies.
- Open Access
TRACK_9: Testosterone replacement assessment: Classical vs. functional hypogonadism‐knowledge from a 9‐year study
Background and objective: The longitudinal efficacy and clinical utility of Testosterone Therapy (TTh) in ameliorating functional hypogonadism (FH) remain contentious, with long‐term data being scarce. To address this lacuna, a comprehensive long‐term registry study, stratifying patients across a spectrum of hypogonadal etiologies, offers a robust investigative paradigm.Materials and methods: This 9‐year registry, encompassing 650 patients (equivalent to 4,362 cumulative years of treatment), included 188 patients diagnosed with FH (mean age 42.3 ± 11.3 years) and 462 individuals with classical hypogonadism (CH). The cohort segregated into 266 men with primary hypogonadism (PH, mean age 34.0 ± 11.7 years) and 196 with secondary hypogonadism (SH, mean age 31.9 ± 12.0 years). Uniform treatment across the cohort involved intramuscular administration of testosterone undecanoate (1,000 mg). A comparative analysis was conducted focusing on anthropometric, metabolic, and safety parameters.Results: Serum testosterone levels increased from 6.6 ± 2.4 to 19.3 ± 2.9 nmol/L (p < 0.001). TTh was linked with weight reduction and decreased waist circumference (WC) in both CH and FH cohorts (both p < 0.001). Cox regression and Kaplan–Meier analyses delineated disparities: men with FH demonstrated a higher propensity for losing > 10% body weight and > 5% WC compared to CH (hazard ratio [HR] 1.3 [1.1–1.4], p = 0.008 and HR 1.4 [1.3–1.5], p = 0.001). Increases in hematocrit > 50% were uniform across groups, albeit amelioration of anemia was more pronounced in FH versus CH (p = 0.002). Increments of prostate‐specific antigen (PSA) levels were more likely to occur in FH (HR 1.3 [1.1–1.6], p = 0.003). FH patients exhibited pronounced improvements in metabolic parameters and in aging male symptom score (AMS) and IIEF‐EF questionnaire scores. These effects were markedly modulated by age and initial weight. Subgroup analysis of age‐matched obese patients revealed an accentuated impact of TTh in CH compared to FH.Discussion and conclusion: The therapeutic outcomes of TTh across distinct hypogonadal populations demonstrate heterogeneous responses, significantly influenced by diagnostic categorization, age, and baseline risk factor profiles.
Open AccessTRACK_9: Testosterone replacement assessment: Classical vs. functional hypogonadism‐knowledge from a 9‐year study
Background and objective: The longitudinal efficacy and clinical utility of Testosterone Therapy (TTh) in ameliorating functional hypogonadism (FH) remain contentious, with long‐term data being scarce. To address this lacuna, a comprehensive long‐term registry study, stratifying patients across a spectrum of hypogonadal etiologies, offers a robust investigative paradigm.Materials and methods: This 9‐year registry, encompassing 650 patients (equivalent to 4,362 cumulative years of treatment), included 188 patients diagnosed with FH (mean age 42.3 ± 11.3 years) and 462 individuals with classical hypogonadism (CH). The cohort segregated into 266 men with primary hypogonadism (PH, mean age 34.0 ± 11.7 years) and 196 with secondary hypogonadism (SH, mean age 31.9 ± 12.0 years). Uniform treatment across the cohort involved intramuscular administration of testosterone undecanoate (1,000 mg). A comparative analysis was conducted focusing on anthropometric, metabolic, and safety parameters.Results: Serum testosterone levels increased from 6.6 ± 2.4 to 19.3 ± 2.9 nmol/L (p < 0.001). TTh was linked with weight reduction and decreased waist circumference (WC) in both CH and FH cohorts (both p < 0.001). Cox regression and Kaplan–Meier analyses delineated disparities: men with FH demonstrated a higher propensity for losing > 10% body weight and > 5% WC compared to CH (hazard ratio [HR] 1.3 [1.1–1.4], p = 0.008 and HR 1.4 [1.3–1.5], p = 0.001). Increases in hematocrit > 50% were uniform across groups, albeit amelioration of anemia was more pronounced in FH versus CH (p = 0.002). Increments of prostate‐specific antigen (PSA) levels were more likely to occur in FH (HR 1.3 [1.1–1.6], p = 0.003). FH patients exhibited pronounced improvements in metabolic parameters and in aging male symptom score (AMS) and IIEF‐EF questionnaire scores. These effects were markedly modulated by age and initial weight. Subgroup analysis of age‐matched obese patients revealed an accentuated impact of TTh in CH compared to FH.Discussion and conclusion: The therapeutic outcomes of TTh across distinct hypogonadal populations demonstrate heterogeneous responses, significantly influenced by diagnostic categorization, age, and baseline risk factor profiles.
- 3 November 2023
- Published by Springer Nature in Die Urologie
- Vol. 62 (12) , 1332-1342
Current treatment concepts for Peyronie’s disease
Zusammenfassung Die Induratio penis plastica (IPP; Morbus Peyronie) ist eine erworbene und chronische Erkrankung des Penis, die durch penile Schmerzen, Verkrümmung und Deformität des Penis sowie daraus resultierende Beeinträchtigungen der sexuellen Aktivität der Patienten gekennzeichnet ist. Als wahrscheinlichste Ursachen gelten Makro- oder Mikrotraumata innerhalb der Tunica albuginea der Corpora cavernosa, welche in der Folge bei einer abnormalen Wundheilung zur Bildung einer Fibrose in diesem Bereich führen. Verschiedene prädisponierende Faktoren und auch eine genetische Veranlagung werden diskutiert. Die IPP tritt am häufigsten im 5. bis 6. Lebensjahrzehnt auf. Die Prävalenz liegt je nach untersuchtem Kollektiv und vorhandenen Risikofaktoren bei 0,3–20 %. Die IPP wird in eine akute inflammatorische Phase und eine chronische postinflammatorische Phase unterteilt. Unterschiedliche konservative und chirurgische Behandlungsoptionen umfassen orale Medikation, die penile Traktionstherapie, intraläsionale Injektionen und chirurgische Verfahren.
- 3 November 2023
- Published by Springer Nature in Die Urologie
- Vol. 62 (12) , 1332-1342
Current treatment concepts for Peyronie’s disease
Zusammenfassung Die Induratio penis plastica (IPP; Morbus Peyronie) ist eine erworbene und chronische Erkrankung des Penis, die durch penile Schmerzen, Verkrümmung und Deformität des Penis sowie daraus resultierende Beeinträchtigungen der sexuellen Aktivität der Patienten gekennzeichnet ist. Als wahrscheinlichste Ursachen gelten Makro- oder Mikrotraumata innerhalb der Tunica albuginea der Corpora cavernosa, welche in der Folge bei einer abnormalen Wundheilung zur Bildung einer Fibrose in diesem Bereich führen. Verschiedene prädisponierende Faktoren und auch eine genetische Veranlagung werden diskutiert. Die IPP tritt am häufigsten im 5. bis 6. Lebensjahrzehnt auf. Die Prävalenz liegt je nach untersuchtem Kollektiv und vorhandenen Risikofaktoren bei 0,3–20 %. Die IPP wird in eine akute inflammatorische Phase und eine chronische postinflammatorische Phase unterteilt. Unterschiedliche konservative und chirurgische Behandlungsoptionen umfassen orale Medikation, die penile Traktionstherapie, intraläsionale Injektionen und chirurgische Verfahren.
- Open Access
Genome-wide DNA methylation changes in human spermatogenesis
Summary: Sperm production and function require the correct establishment of DNA methylation patterns in the germline. Here, we examined the genome-wide DNA methylation changes during human spermatogenesis and its alterations in disturbed spermatogenesis. We found that spermatogenesis is associated with remodeling of the methylome, comprising a global-decline in DNA methylation in primary spermatocytes followed by selective remethylation, resulting in a spermatid-specific methylome. Hypomethylated regions in spermatids were enriched in specific transcription factor binding sites for DMRT and SOX family members and spermatid-specific genes. Intriguingly, while SINEs displayed differential methylation throughout spermatogenesis, LINEs appeared to be protected from changes in DNA methylation. In disturbed spermatogenesis, germ cells exhibited considerable DNA methylation changes, which were significantly enriched at transposable elements and genes involved in spermatogenesis. We detected hypomethylation in SVA and L1HS in disturbed spermatogenesis, suggesting an association between the abnormal programming of these regions and failure of germ cells progressing beyond meiosis.
Open AccessGenome-wide DNA methylation changes in human spermatogenesis
Summary: Sperm production and function require the correct establishment of DNA methylation patterns in the germline. Here, we examined the genome-wide DNA methylation changes during human spermatogenesis and its alterations in disturbed spermatogenesis. We found that spermatogenesis is associated with remodeling of the methylome, comprising a global-decline in DNA methylation in primary spermatocytes followed by selective remethylation, resulting in a spermatid-specific methylome. Hypomethylated regions in spermatids were enriched in specific transcription factor binding sites for DMRT and SOX family members and spermatid-specific genes. Intriguingly, while SINEs displayed differential methylation throughout spermatogenesis, LINEs appeared to be protected from changes in DNA methylation. In disturbed spermatogenesis, germ cells exhibited considerable DNA methylation changes, which were significantly enriched at transposable elements and genes involved in spermatogenesis. We detected hypomethylation in SVA and L1HS in disturbed spermatogenesis, suggesting an association between the abnormal programming of these regions and failure of germ cells progressing beyond meiosis.
- 15 August 2023
- Published by Springer Nature
- p. 477-486
Reproduktive Chancen bei männlichen Jugendlichen und Männern mit Varianten der Geschlechtsentwicklung (DSD)
- 15 August 2023
- Published by Springer Nature
- p. 477-486
Reproduktive Chancen bei männlichen Jugendlichen und Männern mit Varianten der Geschlechtsentwicklung (DSD)